Scientific Reports (Feb 2024)

A bioluminescent and homogeneous assay for monitoring GPCR-mediated cAMP modulation and PDE activity

  • Dareen Mikheil,
  • Matthew A. Larsen,
  • Kevin Hsiao,
  • Nathan H. Murray,
  • Tim Ugo,
  • Hui Wang,
  • Said A. Goueli

DOI
https://doi.org/10.1038/s41598-024-55038-0
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 9

Abstract

Read online

Abstract 3′,5′-Cyclic adenosine monophosphate (cAMP), the first identified second messenger, is implicated in diverse cellular processes involving cellular metabolism, cell proliferation and differentiation, apoptosis, and gene expression. cAMP is synthesized by adenylyl cyclase (AC), which converts ATP to cAMP upon activation of Gαs-protein coupled receptors (GPCRs) in most cases and hydrolyzed by cyclic nucleotide phosphodiesterases (PDEs) to 5′-AMP. Dysregulation of cAMP signaling is implicated in a wide range of pathophysiological conditions such as cardiovascular diseases, neurodegenerative and behavioral disorders, cancers, diabetes, obesity, cataracts, and others. Therefore, cAMP targeted therapies have been and are still undergoing intense investigation for the treatment of these and other diseases. This highlights the need for developing assays to detect and monitor cAMP levels. In this study, we show cAMP Lumit assay as a highly specific homogeneous bioluminescent assay suitable for high throughput screenings with a large assay window and a wide dynamic range for cAMP detection. We believe that this assay will aid and simplify drug discovery screening efforts for cAMP signaling targeted therapies.